US pharma company Bristol-Myers Squibb (NYSE: BMY) has agreed to acquire all the outstanding capital stock of privately-held autoimmune disease treatment developer Padlock Therapeutics in a deal worth up to $600 million.
The acquisition will give Bristol-Myers Squibb full rights to Padlock’s Protein/Peptidyl Arginine Deiminase (PAD) discovery program.
PADs are a family of enzymes that produce autoantigens which play an active role in the development and progression of rheumatoid arthritis (RA) and other autoimmune diseases.
This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.
Login to your accountTry before you buy
7 day trial access
Become a subscriber
Or £77 per month
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed
Chairman, Sanofi Aventis UK
Copyright © The Pharma Letter 2024 | Headless Content Management with Blaze